专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003052425A3 ELISA KIT FOR CYP 2C9 METABOLIC PHENOTYPES 审中-公开
公开(公告)号：WO2003052425A3
公开(公告)日：2003-06-26
申请号：PCT/CA2002/001965
申请日：2002-12-18
申请人： XANTHUS LIFE SCIENCES, INC. , LEYLAND-JONES, Brian
发明人： LEYLAND-JONES, Brian
IPC分类号： G01N33/94
摘要： The invention relates to an enzyme linked immunosorbent assay (ELISA) method and kit for the rapid determination of metabolic phenotypes for Cytochrome P450 2C9 (CYP 2C9). The kit uses may include but are not limited to, use on a routine basis in a clinical laboratory to determine a Cytochrome P450 2C9 (CYP 2C9) phenotype of an individual; to allow a physician to individualize an individual's treatment with respect to the numerous drugs e.g. ibuprofen, losartan, E-3174 and 2-carboxyibuprofen metabolized by CYP 2C9 based on a phenotypic determination; to predict an individual's susceptibility to carcinogen induced diseases including many cancers, and to screen individuals for a preferred metabolic phenotype in order to determine those individuals with a responsive phenotype for participation in clinical testing.

2. 发明申请

WO2003052425A2 ELISA KIT FOR THE DETERMINATION OF CYP 2C9 METABOLIC PHENOTYPES AND USES THEREOF 审中-公开
标题翻译：用于测定CYP 2C9代谢基因的ELISA试剂盒及其用途
公开(公告)号：WO2003052425A2
公开(公告)日：2003-06-26
申请号：PCT/CA2002/001965
申请日：2002-12-18
申请人： XANTHUS LIFE SCIENCES, INC. , LEYLAND-JONES, Brian
发明人： LEYLAND-JONES, Brian
IPC分类号： G01N33/94
CPC分类号： G01N33/50 , C12Q1/26 , G01N33/9486 , G01N2333/90209 , G01N2333/90245
摘要： The invention relates to an enzyme linked immunosorbent assay (ELISA) method and kit for the rapid determination of metabolic phenotypes for Cytochrome P450 2C9 (CYP 2C9). The kit uses may include but are not limited to, use on a routine basis in a clinical laboratory to determine a Cytochrome P450 2C9 (CYP 2C9) phenotype of an individual; to allow a physician to individualize an individual's treatment with respect to the numerous drugs e.g. ibuprofen, losartan, E-3174 and 2-carboxyibuprofen metabolized by CYP 2C9 based on a phenotypic determination; to predict an individual's susceptibility to carcinogen induced diseases including many cancers, and to screen individuals for a preferred metabolic phenotype in order to determine those individuals with a responsive phenotype for participation in clinical testing.
摘要翻译：本发明涉及用于快速测定细胞色素P450 2C9（CYP 2C9）的代谢表型的酶联免疫吸附测定（ELISA）方法和试剂盒。试剂盒的用途可以包括但不限于在临床实验室中常规使用以确定个体的细胞色素P450 2C9（CYP 2C9）表型; 使医生能够针对多种药物个体化个体治疗。基于表型测定，由CYP 2C9代谢的布洛芬，氯沙坦，E-3174和2-羧基布洛芬; 预测个体对包括许多癌症在内的致癌物质疾病的敏感性，并筛选个体以获得优选的代谢表型，以便确定具有参与临床测试的响应表型的那些个体。

3. 发明申请

WO2003052123A1 INDIVIDUALIZATION OF THERAPY WITH ANTIHISTAMINES 审中-公开
标题翻译：用抗生素治疗的个体化
公开(公告)号：WO2003052123A1
公开(公告)日：2003-06-26
申请号：PCT/CA2002/001962
申请日：2002-12-18
申请人： XANTHUS LIFE SCIENCES, INC. , LEYLAND-JONES, Brian
发明人： LEYLAND-JONES, Brian
IPC分类号： C12Q1/00
CPC分类号： B82Y30/00 , C12Q1/26 , G01N33/5088
摘要： The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antihistamines.
摘要翻译：本发明涉及基于个体的表型谱的个体化治疗。更具体地，本发明涉及代谢表型用于抗组胺药治疗个体化的用途。

4. 发明申请

WO2003008637A2 USE OF GENOTYPING IN THE INDIVIDUALIZATION OF THERAPY 审中-公开
标题翻译：基因治疗在治疗个体化中的应用
公开(公告)号：WO2003008637A2
公开(公告)日：2003-01-30
申请号：PCT/CA2002/001103
申请日：2002-07-17
申请人： MCGILL UNIVERSITY , LEYLAND-JONES, Brian
发明人： LEYLAND-JONES, Brian
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172 , G06F19/00 , Y02A90/22 , Y02A90/26
摘要： The invention relates to the individualization of therapy. More specifically, the present invention relates to the use of genotyping for the individualization of therapy and/or individualization of drug dosing. More specifically, the present invention relates to the use of genotyping in the individualization of therapy with a therapeutic agent or a class of therapeutic agents.
摘要翻译：本发明涉及治疗的个体化。更具体地，本发明涉及用于个体化治疗和/或药物给药的个体化的基因分型。更具体地说，本发明涉及基因分型在用治疗剂或一类治疗剂的治疗个体化中的用途。

5. 发明申请

WO2002073196A2 INDIVIDUALIZATION OF THERAPY WITH ANTIPSYCHOTICS 审中-公开
标题翻译：用抗精神病药物进行个体化治疗
公开(公告)号：WO2002073196A2
公开(公告)日：2002-09-19
申请号：PCT/CA2002/000343
申请日：2002-03-14
申请人： MCGILL UNIVERSITY , LEYLAND-JONES, Brian
发明人： LEYLAND-JONES, Brian
IPC分类号： G01N33/53
CPC分类号： B82Y30/00 , C12Q1/26 , C12Q1/48 , G01N33/94 , G01N33/9426 , G01N33/9466 , G01N33/948 , G01N2333/90245 , G01N2333/91057 , G01N2333/91171 , G01N2333/91245
摘要： The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antipsychotic agents.
摘要翻译：本发明涉及基于个体的表型谱的个体化治疗。更具体地说，本发明涉及代谢表型用于抗精神病药物治疗的个体化的用途。

6. 发明申请

WO02064816A2 MULTIPLE DETERMINANTS FOR METABOLIC PHENOTYPES 审中-公开
标题翻译：多种代谢物的决定因素
公开(公告)号：WO02064816A2
公开(公告)日：2002-08-22
申请号：PCT/CA0200161
申请日：2002-02-08
申请人： UNIV MCGILL , LEYLAND-JONES BRIAN
发明人： LEYLAND-JONES BRIAN
IPC分类号： A61K38/43 , C12Q1/48 , G01N33/50 , G01N33/94 , C12Q1/00
CPC分类号： B82Y30/00 , A61K31/135 , C12Q1/48 , G01N33/5088 , G01N33/948 , G01N2800/52
摘要： The invention relates to the determination of multiple phenotypic determinants for human drug metabolizing enzymes. More specifically, the present invention relates to the characterization of metabolic phenotypes based on phenotypic determinants and applications and uses thereof.
摘要翻译：本发明涉及确定人类药物代谢酶的多种表型决定簇。更具体地，本发明涉及基于表型决定因素及其应用和用途的代谢表型的表征。

7. 发明申请

WO0055624A3 ELISA KIT FOR THE DETERMINATION OF METABOLIC PHENOTYPES 审中-公开
标题翻译：用于确定代谢基因的ELISA试剂盒
公开(公告)号：WO0055624A3
公开(公告)日：2001-02-01
申请号：PCT/CA0000246
申请日：2000-03-09
申请人： LEYLAND JONES BRIAN , WONG PIERRE
发明人： LEYLAND-JONES BRIAN , WONG PIERRE
IPC分类号： G01N33/53 , G01N33/543 , G01N33/94 , C07D473/08 , C07D473/10 , C07D473/12
CPC分类号： G01N33/94 , G01N2800/52
摘要： The invention relates to an enzyme linked immunosorbent assay (ELISA) kit for the rapid determination of metabolic phenotypes including but not limited to CYP 1A2, N-acetyltamferase-1 (NAT-1), CYP 2P6, CYP 2E1 and CYP 3A4, which can be used on a routine basis in a clinical laboratory. The ELISA kit allows physicians to a) individualize therapy of drugs such as theophylline, tamoxifen, and clozapine and b) to predict susceptibility to carcinogen induced diseases such as colon rectal cancers. To reduce the number of patients undergoing clinical testing by selecting for patients with the appropriate phenotype most likely to respond.
摘要翻译：本发明涉及用于快速测定代谢表型的酶联免疫吸附测定（ELISA）试剂盒，其包括但不限于CYP 1A2，N-乙酰基转移酶-1（NAT-1），CYP2P6，CYP2E1和CYP3A4，其可以在临床实验室中常规使用。 ELISA试剂盒允许医师a）个体化药物如茶碱，他莫昔芬和氯氮平的治疗，以及b）预测致癌物诱导的疾病如结肠直肠癌的易感性。通过选择最有可能应答的适当表型的患者，减少接受临床检测的患者人数。

8. 发明申请

WO2010056993A2 PROSTATE CANCER BIOMARKERS TO PREDICT RECURRENCE AND METASTATIC POTENTIAL 审中-公开
标题翻译：预测癌症生物标志物预测复发和分化潜力
公开(公告)号：WO2010056993A2
公开(公告)日：2010-05-20
申请号：PCT/US2009/064384
申请日：2009-11-13
申请人： EMORY UNIVERSITY , MORENO, Carlos , OSUNKOYA, Adeboye , ZHOU, Wei , LEYLAND-JONES, Brian , LONG, Qi , JOHNSON, Brent A.
发明人： MORENO, Carlos , OSUNKOYA, Adeboye , ZHOU, Wei , LEYLAND-JONES, Brian , LONG, Qi , JOHNSON, Brent A.
IPC分类号： C12Q1/68 , C12N15/12 , G06F19/00
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/16 , C12Q2600/178 , G06F19/20 , G06F19/24
摘要： Described herein are methods for predicting the recurrence, progression, and metastatic potential of a prostate cancer in a subject. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of FOXO1A, SOX9, CLNS1A, PTGDS, XPO1, LETMD1, RAD23B, ABCC3, APC, CHES1, EDNRA, FRZB, HSPG2, and TMPRSS2_ETV1 FUSION. The method can further comprise detecting in a sample from a subject one or more biomarkers selected from the group consisting of miR-103, miR-339, miR-183, miR-182, miR-136, and miR-221. An increase or decrease in one or more biomarkers as compared to a standard indicates a recurrent, progressive, or metastatic prostate cancer.
摘要翻译：本文描述了用于预测受试者中前列腺癌的复发，进展和转移潜能的方法。例如，该方法包括在受试者的一个样品中检测一种或多种选自FOXO1A，SOX9，CLNS1A，PTGDS，XPO1，LETMD1，RAD23B，ABCC3，APC，CHES1，EDNRA，FRZB，HSPG2和 TMPRSS2_ETV1 FUSION。该方法还可以包括在受试者的样品中检测一种或多种选自miR-103，miR-339，miR-183，miR-182，miR-136和miR-221的生物标志物。与标准物相比，一种或多种生物标志物的增加或减少表示复发，进行性或转移性前列腺癌。

9. 发明申请

WO02084288A9 INDIVIDUALIZATION OF THERAPY WITH ANTIARRHYTHMICS 审中-公开
标题翻译：治疗与抗精神病药物的个体化
公开(公告)号：WO02084288A9
公开(公告)日：2004-05-27
申请号：PCT/CA0200525
申请日：2002-04-17
申请人： UNIV MCGILL , LEYLAND-JONES BRIAN
发明人： LEYLAND-JONES BRIAN
IPC分类号： A61P9/00 , C12Q1/26 , G01N33/94 , G01N33/53 , C12Q1/00
CPC分类号： B82Y30/00 , C12Q1/26 , G01N33/9453
摘要： The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antiarrythmics.
摘要翻译：本发明涉及基于个体的表型谱的个体化治疗。更具体地说，本发明涉及代谢分型用于抗糖尿病治疗个体化的用途。

10. 发明申请

WO2004003550A2 INDIVIDUALIZATION OF THERAPY WITH ANTICOAGULANTS 审中-公开
标题翻译：治疗与抗生素的个体化
公开(公告)号：WO2004003550A2
公开(公告)日：2004-01-08
申请号：PCT/CA2003/000978
申请日：2003-06-27
申请人： XANTHUS LIFE SCIENCES, INC. , LEYLAND-JONES, Brian
发明人： LEYLAND-JONES, Brian
IPC分类号： G01N33/53
CPC分类号： B82Y30/00 , C07D311/56 , C07K16/16 , C12Q1/56 , G01N33/5091
摘要： The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with anticoagulants.
摘要翻译：本发明涉及基于个体的表型谱的个体化治疗。更具体地，本发明涉及代谢分型用于抗凝药物治疗个体化的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式